Christian Schade - Feb 25, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Chairman & CEO, Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Feb 25, 2022
Transactions value $
-$37,661
Form type
4
Date filed
3/1/2022, 04:02 PM
Previous filing
May 17, 2021
Next filing
Mar 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Tax liability -$37.7K -21.6K -12.25% $1.74 155K Feb 25, 2022 Direct F1
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 1K Feb 25, 2022 By adult child F2
holding APRE Common Stock 5K Feb 25, 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 55,166 restricted stock units.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.